AL_ER: Affect Labeling - Experimental Evaluation and Behavioral Intervention

Sponsor
Karolinska Institutet (Other)
Overall Status
Suspended
CT.gov ID
NCT04826874
Collaborator
(none)
154
1
2
33
4.7

Study Details

Study Description

Brief Summary

The overall aim of this project is to better understand the emotion regulating effect of labeling emotions (affecting labeling, AL) for individuals with self-perceived emotional regulation difficulties from both a clinical population and a non-clinical population, by using both self-assessment and psychophysiological testing of emotional activation. The main part of the project includes a brief intervention aiming to test the emotion-regulating effect of a short behavioral intervention to learn and practice AL. This two-week intervention, aims to improve the ability to regulate emotions, and to assess the benefits of emotion regulation strategies for individuals with and without a clinical diagnosis, but with self-perceived difficulties in emotion regulation.

The second part of this study aims to conceptually replicate a previous basic research study on AL and its emotion-regulating effect in a experimental laboratory setting and to extend that replication to include a clinical group. The replication contributes to an indepth understanding of AL as an implicit emotion regulation strategy in the short term, i.e. as a strategy used directly in the emotionally charged situation, and expands that knowledge to also include the effect in individuals with a clinical diagnosis. Also, it provides the opportunity to evaluate the effect of the two week AL behavioral intervention using psychophysiological testing.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Affect labeling
N/A

Detailed Description

Main study: AFFECT LABELING - DAILY EXERCISE IN PUTTING WORDS ON EMOTIONS DESIGN AND PROCEDURE This clinical study is a randomized, wait-list controlled design with repeated measurements. Participants are randomized at inclusion between being directly offered a 14-day course to train AL and waiting two weeks before beginning the intervention. Participants are blind to this randomization and do not know that they are in the waitlist condition, in order to avoid nocebo effects. The randomization is done 1: 1, and stratified by clinical categorization (participants with or without a psychiatric diagnosis).

The course is given via a secure web platform (BASS4) in which the participant also makes all their assessments, and interacts with the study material and their course leader (clinical psychologist or master level psychology students).

Intervention - web course in affect labeling The intervention is given as a two week internet-delivered course in using AL with the guidance of a course leader (licensed psychologist or psychologist assistant under supervision). The course is divided into two modules where module 1 contains a) Psychoeducation about different emotions and its function,

  1. Information about AL and its potential emotion-regulating effect, c) Instruction on how to use AL in everyday life and d) Planning of daily short exercises in naming emotions. Daily registration with multiple choice answers is introduced to help the practice of AL. All assessments are web-based and reminders are sent to the participants' cellphone. The course leader is active in providing feedback on the exercises and planning.

Module 2 is largely a continuation of module 1 where any obstacles and other difficulties are discussed in order to increase the chance of active practice in AL, and continued daily practice. Module 3 is a brief summary of what has been taught and is made available to the participant after post-assessment.

Laboratory sub-study: Participants will also participate in a laboratory-based study where the emotion regulating effect of AL will be compared with distraction or passive viewing while being exposed to emotionally provocative visual stimuli. Participants are exposed to 3 blocks of 8 images and questions about the images ("trials") with equal numbers of negative and neutral valence in three conditions: instruction to "Watch", instruction to use AL and instruction to use Distraction. The instructions and pictures are given in a randomized, balanced order. Before each block, a 3-second instruction is displayed that indicates whether the participant should use "Watch", "AL" or "Distraction" for all 8 images in the block.

All participants will carry out the laboratory sub-study on two occasions: before and after the 14 day period it takes for the individuals who directly receives the web-based course in AL to complete it.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
154 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
within-individual and randomized control designwithin-individual and randomized control design
Masking:
Single (Participant)
Primary Purpose:
Basic Science
Official Title:
Affect Labeling - Experimental Evaluation and Behavioral Intervention
Actual Study Start Date :
Mar 31, 2021
Anticipated Primary Completion Date :
May 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Affect Labeling_direct

Randomized to immediate two-week, internet delivered psychoeducative course in affect labeling

Behavioral: Affect labeling
Short behavioral intervention teaching affect labeling

No Intervention: Wait-list

Randomized to a two-week wait-list control

Outcome Measures

Primary Outcome Measures

  1. Change in The Difficulties in Emotion Regulation Scale, DERS (Gratz & Roemer, 2004) [At day 1 and at day 14 (+/- 5 days)]

    Min 36, Max 180. Higher scores represents worse outcome

Secondary Outcome Measures

  1. The Patient Health Questionnaire (PHQ-9; Kroenke, Spitzer, & Williams, 2001) [At baseline and day 14 (+/- 5 days)]

    Min 0, Max 27. Higher scores represents worse outcome

  2. The Generalized Anxiety Disorder 7-item Scale (GAD-7; Spitzer, Kroenke, Williams, & Löwe, 2006). [At baseline and day 14 (+/- 5 days)]

    Min 0, Max 21. Higher scores represents worse outcome

  3. The Emotion Regulation Questionnaire (ERQ; Gross & John, 2003) [At day 1 and day 14 (+/- 5 days)]

    Two sub scales: Cognitive reappraisal: Min 6 Max 42. Higher scores represents higher use of reappraisal. Suppression: Min 4 Max 28. Higher scores represents more use of suppression.

  4. The Toronto Alexithymia Scale (TAS-20; Bagby et al., 1994). [At baseline and day 14 (+/- 5 days)]

    Min 20, Max 100. Higher scores represents worse outcome

  5. The Ruminative responses scale - Brooding and Reflection (RRS-BR; Treynor et al., 2003, Cronwall, 2019). [At baseline and day 14 (+/- 5 days)]

    Min 10 Max 40. Higher scores represents worse outcome

  6. the Client Satisfaction Questionnaire, 8 item (CSQ-8; Attkisson & Zwick, 1982). [At day 14 (+/- 5 days)]

    Min 8 Max 32 Higher scores represents better outcome

  7. Levels of expected emotional upset [At day 1 and day 14 (+/- 5 days)]

    9-degree Likert scale. Min 1 (Not upset at all) Max 9 (Very upset).

  8. Change in skin conductance response between three different emotion regulation conditions [3*8*5 seconds at Day 1 and at Day 14 (+/-5 days)]

    change of skin conductance (micro-Siemens (μS)) averaged over a 5 sec time window, and repeated 8 times per condition, ie. 8*5 seconds repeated 3 times.

  9. Change in Heart Rate Variability (HRV) (micro-Siemens (μS)) averaged over a 5 sec time window, and repeated 8 times per condition, ie. 8*5 seconds repeated 3 times. [At day 1 and at day 14 (+/- 5 days)]

    Heart Rate Variability is a measure which indicates the variation in your heartbeats within a specific timeframe.

  10. Change in pupillometry (micro-Siemens (μS)) averaged over a 5 sec time window, and repeated 8 times per condition, ie. 8*5 seconds repeated 3 times. [At day 1 and at day 14 (+/- 5 days)]

    Change in pupil size from baseline in response to the presentation of a stimulus

  11. Change in The Affect Labeling Questionnaire, ALQ (Sahi, et al. (in prep) [At day 1 and at day 14 (+/- 5 days)]

    Min 12, Max 60. Higher scores represents better outcome

  12. Change in Experienced emotional upset (Time frame: averaged over a 5 sec time window, repeated 24 times during the experiment) [At day 1 and day 14 (+/- 5 days)]

    9-degree Likert scale. Min 1 (Not upset at all) Max 9 (Very upset).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Sufficient skills in Swedish to be able to fill in self-assessment questionnaires.

  • State at least a 3 (or higher) out of 10 regarding everyday difficulties with emotion regulation according to a scale created for this purpose: Do you feel that you currently have problems regulating your emotions? Circle the number that is best for you "(0 no problems at all, 10 Very severe problems.

  • Answer "Yes, very much" or "Yes" to the following question: "Would you like to learn to regulate/manage your emotions better?" with the options "Yes, very much / Yes / Maybe, but doubtful if it is worth the effort, does not fit right now / No".

Exclusion Criteria:
  • Psychiatric or somatic status that may prevent the participant from completing the experiment or require some form of care intervention the participant does not already undergo.

  • Medium to high risk of suicide.

  • Moderate to severe self-harming behavior.

  • Blood phobia.

  • Regular medication with benzodiazepines (including sleep medication, ex Stilnoct).

  • Ongoing treatment with emotion regulation elements.

To be part of the clinical group, the participant must state a diagnosis established by a medical professional in the last 5 years, which involves clinical difficulties with emotion regulation such as binge eating disorder, emotional instability, generalized anxiety, depression, social anxiety or ADHD, and does not plan to start, change or discontinue any psychosocial or pharmacological treatment within the next 4 weeks. The non-clinical group must not have been diagnosed or treated for mental illness in the last 5 years.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Karolinska Institutet, department of clinical neuroscience Stockholm Sweden 17177

Sponsors and Collaborators

  • Karolinska Institutet

Investigators

  • Principal Investigator: Hanna Sahlin, Med Dr, Karolinska Institutet

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hanna Sahlin, Principal investigator, PhD, Karolinska Institutet
ClinicalTrials.gov Identifier:
NCT04826874
Other Study ID Numbers:
  • 2020-06427
First Posted:
Apr 1, 2021
Last Update Posted:
Jun 21, 2022
Last Verified:
Jun 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Hanna Sahlin, Principal investigator, PhD, Karolinska Institutet

Study Results

No Results Posted as of Jun 21, 2022